dicycloplatin (DCP) / Sopo-Xingda Pharma, Bioplatin - LARVOL DELTA

Dicycloplatin, a Novel Analog of Cisplatin and Carboplatin, May Provide Therapeutic Advancement in Cancer Chemotherapy. (PubMed, Anticancer Res) - "While more extensive clinical trials are needed, particularly in Western populations. Current data suggest that DCP may represent a significant advancement in platinum-based chemotherapy, potentially offering improved quality of life for cancer patients without compromising treatment efficacy."

Journal • Review • Bladder Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Lung Cancer • Oncology • Solid Tumor

The Novel Platinum Analog Dicycloplatin Provides Reliable Growth Inhibition of Urothelial Carcinoma Cells In Vitro. (PubMed, Anticancer Res) - "In vitro, DCP demonstrates cell-killing efficacy in a time- and concentration-dependent manner in grade II-IV UC cell lines, showing promise for its intravenous, oral, and intravesical use for bladder UC in both primary and adjuvant/neoadjuvant settings."

Journal • Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Dicycloplatin: Assessing the efficacy of a novel platinum analog for treatment of urothelial carcinoma of the bladder. (ASCO-GU 2024) - " A high grade (IV) in vitro UC cell line (TCCSUP) was exposed to varying concentrations of cisplatin (0-600 ug/mL), carboplatin (0-600 ug/mL), oxaliplatin (0-4.0 ug/mL), and DCP (0-350 ug/mL). DCP has in vitro cell-kill efficacy in a time- and concentration-dependent manner in grade II-IV UC cell lines, showing promise for its IV, PO, and intravesical use for UC of the bladder in the primary and adjuvant/neoadjuvant setting. Animal studies are forthcoming to assess in vivo efficacy prior to proceeding with clinical trials."

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Dicycloplatin: Use of a Novel Platinum Analog in Treatment of Urothelial Carcinoma in Nude Mice (MA-AUA 2023) - No abstract available

Preclinical • Oncology • Solid Tumor • Urothelial Cancer

USE OF THE NOVEL PLATINUM ANALOG DICYCLOPLATIN IN TREATMENT OF UROTHELIAL CARCINOMA OF THE BLADDER (SUO 2022) - " Our high grade (IV) in vitro bladder TCC cell line (TCCSUP) was exposed to varying concentrations of cisplatin (0-600 ug/mL), carboplatin (0-600 ug/mL), oxaliplatin (0-4.0 ug/mL), and DCP (0-350 ug/mL). Our results show in vitro cell-kill efficacy of DCP in a time and concentration-dependent manner in grade II-IV TCC cell lines, showing promise for its IV, PO, and intravesical use for TCC of the bladder in the primary and adjuvant/neoadjuvant setting. Studies in progress seek to assess bioavailability, efficacy, and safety in vivo in a mouse model prior to moving to early-phase clinical trials."

Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

TACE With Dicycloplatin(TP21) in Unresectable HCC (clinicaltrials.gov) - P3 | N=332 | Recruiting | Sponsor: Gao-jun Teng

New P3 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor